Vodafone has signed a global partnership with AstraZeneca in order to develop m-health services to improve the outcome for patients with cardiovascular conditions. The collaboration will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more effectively, according to the press release.
AstraZeneca’s Intelligent Pharmaceutical Group will lead the project with Vodafone charged with providing the technology, infrastructure and expertise for the new services.
The UK-based operator said it will also look to capture data from a variety of sources to improve overall engagement between patients and healthcare professionals. All the new services will be designed to work across geographies.
“Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients,” according to a comment attributed to Vodafone M2M Director Erik Brennais. But there is little in the way of details of what the two companies may develop or the timescales.